Raya Tcheroyan

Raya Tcheroyan

Auto-generated profile, based on publicly available information

Raya Tcheroyan

Faculty of Medicine and Medical Center, American University of Beirut, Beirut, Lebanon

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2023 in eClinicalMedicine
Verified
Journal Article
Open access
MCMarlene Chakhtoura
Marlene Chakhtoura
RHRachelle Haber
Rachelle Haber
MGMalak Ghezzawi
Malak Ghezzawi
CRCaline Rhayem
Caline Rhayem
RTRaya Tcheroyan
Raya Tcheroyan
CMChristos S. Mantzoros
Christos S. Mantzoros
Obesity is an epidemic and a public health threat. Medical weight management remains one of the options for the treatment of excess weight and recent advances have revolutionized how we treat, and more importantly how we will be treating obesity in the near future. Metreleptin and Setmelanotide are currently indicated for rare obesity syndromes, and 5 other medications (orlistat, phentermine/topiramate, naltrexone/bupropion, liraglutide, semaglutide) are approved for non-syndromic obesity. Tirzepatide is about to be approved, and other drugs, with exciting novel mechanisms of action primarily based on incretins, are currently being investigated in different phases of clinical trials. The majority of these compounds act centrally, to reduce appetite and increase satiety, and secondarily, in the gastrointestinal tract to slow gastric emptying. All anti-obesity medications improve weight and metabolic parameters, with variable potency and effects depending on the specific drug. The currently available data do not support a reduction in hard cardiovascular outcomes, but it is almost certain that such data are forthcoming in the very near future. The choice of the anti-obesity medication needs to take into consideration the patient's clinical and biochemical profile, co-morbidities, and drug contra-indications, as well as expected degree of weight loss and improvements in cardio-renal and metabolic risk. It also remains to be seen whether precision medicine may offer personalized solutions to individuals with obesity, and whether it may represent the future of medical weight management along with the development of novel, very potent, anti-obesity medications currently in the pipeline. None.

22 September 2021 in Journal of Global Health Reports
Verified
Journal Article
Open access
PDF file
PMPeter Makhoul
Peter Makhoul
RTRaya Tcheroyan
Raya Tcheroyan
WAWalid Ammar
Walid Ammar
RHRanda Hamadeh
Randa Hamadeh
PZPierre Zalloua
Pierre Zalloua
GNGhassan Nabbout
Ghassan Nabbout
Background: The war in Syria triggered the influx of a large number of refugees into neighboring countries, particularly Lebanon. In 2019, the Syrian population made up 13.33% of the total population in Lebanon. This shift in demographics influenced many sectors in the country, including the healthcare system. The purpose of this study is to analyze the impact of Syrian refugees on the Lebanese healthcare system across five public health centers (PHCs) and the prevalence of type II diabetes (T2D) in these patients. Methods: Patient data was collected across five PHCs from different regions in Lebanon. Comparisons between Lebanese and Syrian patients were analyzed for demographics, relative number of patients, and prevalence of T2D. Results: We found that the number of patients admitted to PHCs has increased over the last few years, in both Syrian and Lebanese populations, putting more strains on an already threatened sector. In addition, the increase in Lebanese patients is significantly higher after 2015, and it parallels the surge in Syrian immigrants. The prevalence of T2D was found to be increasing over the years among the two populations, with a statistically significant increase in the Lebanese population after 2015. However, the prevalence of T2D was found to be statistically lower than the reported national prevalence in both groups, possibly due to inadequate rates of screening. Conclusions: There has been an increase in admissions to PHCs as well as rates of T2D in Lebanon and in the Syrian population. Inadequate screening could be the reason behind the lower prevalence of T2D in our study compared to the reported national prevalence.